



The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 28 June 2001
CPMP/1935/01

PRESS RELEASE

Committee for Proprietary Medicinal Products Meeting of 26 to 28 June 2001

The CPMP adopted one opinion on initial marketing authorisation applications at this meeting:

- Positive opinion on appeal for Scotia Pharmaceuticals Ltd's Foscan (temoporfin) indicated for the palliative treatment of advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.

The summary of opinion is available on the EMEA web site.

As part of the Committee's ongoing scientific review on cardiovascular risks on third generation oral contraceptives, the CPMP considered further information from marketing authorisation holders. The CPMP will continue its discussions at its next meeting on 24 to 26 July 2001.

A more detailed CPMP meeting report will be made available next week, including a position statement from the EMEA on the use of placebo in clinical trials with regard to the revised Declaration of Helsinki and also details from the MRFG meeting of 25 June 2001.

--ENDS--

For further information please contact:

Noël Wathion
Head of Unit
Post-authorisation evaluation of medicinal products
Tel. (44-20) 74 18 85 92